These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38331200)

  • 41. Immunoglobulin A response to SARS-CoV-2 infection and immunity.
    Esmat K; Jamil B; Kheder RK; Kombe Kombe AJ; Zeng W; Ma H; Jin T
    Heliyon; 2024 Jan; 10(1):e24031. PubMed ID: 38230244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Promises and challenges of mucosal COVID-19 vaccines.
    Rathore APS; St John AL
    Vaccine; 2023 Jun; 41(27):4042-4049. PubMed ID: 37045682
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
    Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
    Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection.
    Fröberg J; Diavatopoulos DA
    Curr Opin Infect Dis; 2021 Jun; 34(3):181-186. PubMed ID: 33899752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    Chaparian RR; Harding AT; Hamele CE; Riebe K; Karlsson A; Sempowski GD; Heaton NS; Heaton BE
    J Virol; 2022 Aug; 96(15):e0068922. PubMed ID: 35862698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines.
    Mouro V; Fischer A
    Mucosal Immunol; 2022 Apr; 15(4):584-594. PubMed ID: 35505121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults.
    Surie D; Yuengling KA; DeCuir J; Zhu Y; Lauring AS; Gaglani M; Ghamande S; Peltan ID; Brown SM; Ginde AA; Martinez A; Mohr NM; Gibbs KW; Hager DN; Ali H; Prekker ME; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Leis AM; Khan A; Hough CL; Bender WS; Duggal A; Bendall EE; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Shapiro NI; Columbus C; Vaughn IA; Ramesh M; Mosier JM; Safdar B; Casey JD; Talbot HK; Rice TW; Halasa N; Chappell JD; Grijalva CG; Baughman A; Womack KN; Swan SA; Johnson CA; Lwin CT; Lewis NM; Ellington S; McMorrow ML; Martin ET; Self WH;
    JAMA Netw Open; 2024 Apr; 7(4):e244954. PubMed ID: 38573635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience.
    Pilapitiya D; Wheatley AK; Tan HX
    EBioMedicine; 2023 Jun; 92():104585. PubMed ID: 37146404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice.
    Ashhurst AS; Johansen MD; Maxwell JWC; Stockdale S; Ashley CL; Aggarwal A; Siddiquee R; Miemczyk S; Nguyen DH; Mackay JP; Counoupas C; Byrne SN; Turville S; Steain M; Triccas JA; Hansbro PM; Payne RJ; Britton WJ
    Nat Commun; 2022 Nov; 13(1):6972. PubMed ID: 36379950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.
    Garg R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Hum Vaccin Immunother; 2017 Dec; 13(12):2894-2901. PubMed ID: 28825870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection.
    Sheikh-Mohamed S; Isho B; Chao GYC; Zuo M; Cohen C; Lustig Y; Nahass GR; Salomon-Shulman RE; Blacker G; Fazel-Zarandi M; Rathod B; Colwill K; Jamal A; Li Z; de Launay KQ; Takaoka A; Garnham-Takaoka J; Patel A; Fahim C; Paterson A; Li AX; Haq N; Barati S; Gilbert L; Green K; Mozafarihashjin M; Samaan P; Budylowski P; Siqueira WL; Mubareka S; Ostrowski M; Rini JM; Rojas OL; Weissman IL; Tal MC; McGeer A; Regev-Yochay G; Straus S; Gingras AC; Gommerman JL
    Mucosal Immunol; 2022 May; 15(5):799-808. PubMed ID: 35468942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resurgence of influenza and respiratory syncytial virus in Egypt following two years of decline during the COVID-19 pandemic: outpatient clinic survey of infants and children, October 2022.
    Kandeel A; Fahim M; Deghedy O; Roshdy WH; Khalifa MK; Shesheny RE; Kandeil A; Naguib A; Afifi S; Mohsen A; Abdelghaffar K
    BMC Public Health; 2023 Jun; 23(1):1067. PubMed ID: 37277781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines.
    Fraser R; Orta-Resendiz A; Mazein A; Dockrell DH
    Trends Mol Med; 2023 Apr; 29(4):255-267. PubMed ID: 36764906
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival of Vaccine-Induced Human Milk SARS-CoV-2 IgG, IgA and SIgA Immunoglobulins across Simulated Human Infant Gastrointestinal Digestion.
    Pieri M; Maniori MA; Shahabian L; Kanaan E; Paphiti-Demetriou I; Pipis S; Felekkis K; Nicolaidou V; Papaneophytou C
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination.
    Ota K; Sakai H; Sasaki D; Mitsumoto-Kaseida F; Sakamoto K; Kosai K; Hasegawa H; Takazono T; Izumikawa K; Mukae H; Tun MMN; Morita K; Yanagihara K
    Virus Res; 2024 Jan; 339():199294. PubMed ID: 38056502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Secretory IgA Response in Human Milk Against the SARS-CoV-2 Spike Is Highly Durable and Neutralizing for At Least 1 Year of Lactation Postinfection.
    Yang X; Fox A; DeCarlo C; Pineda N; Powell RLR
    Breastfeed Med; 2023 Aug; 18(8):602-611. PubMed ID: 37615565
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.